Anti-Therapeutic Action: psychosis

A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics

mycolabadmin

Psychedelic compounds like psilocybin and ketamine show promise in treating serious mental health conditions including PTSD and depression. The FDA carefully evaluates these drugs through multi-phase clinical trials to ensure they are safe and effective. While California has proposed making psychedelics more widely available through legislation, the FDA’s thorough approval process provides important protections by identifying potential risks and ensuring proper medical oversight.

Read More »

Toxicology and Analysis of Psychoactive Tryptamines

mycolabadmin

Tryptamines are a growing class of psychoactive drugs that can cause hallucinations and other dramatic changes in perception. These substances, including compounds like DMT and psilocybin from magic mushrooms, work by affecting serotonin receptors in the brain. While some research explores their potential medical use for treating depression and anxiety, they also carry serious risks including dangerous changes in heart rate, body temperature, and mental state. Scientists have developed new laboratory methods to detect these drugs in blood and urine samples to help doctors diagnose and treat overdoses.

Read More »

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

mycolabadmin

This review examines how psilocybin, the active compound in magic mushrooms, may help treat difficult-to-treat conditions like smoking addiction, alcohol dependence, and depression. Clinical trials show psilocybin-assisted therapy achieves better smoking cessation rates (80%) than standard medications and reduces depression symptoms as effectively as common antidepressants. The treatment works differently than daily medications, requiring only a few supervised doses weeks apart, potentially offering a new option for millions of people.

Read More »
Scroll to Top